Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 177.50p 175.00p 180.00p 177.50p 177.50p 177.50p 556 07:47:32
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.3 -25.7 -35.0 - 109.92

Summit Corp (SUMM) Latest News

More Summit Corp News
Summit Corp Takeover Rumours

Summit Corp (SUMM) Share Charts

1 Year Summit Corp Chart

1 Year Summit Corp Chart

1 Month Summit Corp Chart

1 Month Summit Corp Chart

Intraday Summit Corp Chart

Intraday Summit Corp Chart

Summit Corp (SUMM) Discussions and Chat

Summit Corp Forums and Chat

Date Time Title Posts
18/1/201821:17Summit - Climbing to new heights23,147
12/11/201702:48Summit Therapeutics' View on Utrophin Modulation-
10/3/201615:43Professor Mark Wilcox Interview on C Diff1
23/5/201409:49Summit Corporation749
22/5/201416:46Summit Corporation plc37

Add a New Thread

Summit Corp (SUMM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Summit Corp trades in real-time

Summit Corp (SUMM) Top Chat Posts

DateSubject
21/1/2018
08:20
Summit Corp Daily Update: Summit Corporation is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Corp was 177.50p.
Summit Corporation has a 4 week average price of 165p and a 12 week average price of 140p.
The 1 year high share price is 265p while the 1 year low share price is currently 140p.
There are currently 61,927,658 shares in issue and the average daily traded volume is 87,327 shares. The market capitalisation of Summit Corporation is £109,921,592.95.
04/1/2018
20:54
euroto: Be aware folks that the share price data on the other BB is currently not accurate.
03/1/2018
14:52
chrisatrdg: Below are ddubya's comments from the other board following Free - Money's comments relating to todays conference - 'That seems like a pretty concise summary FM. Not enough to move the share price upwards but positive long term and with the possibility of some income from the Roche/Discuva arrangements. The only thing I would add is that the first DMD results are confirmed as on track for Q1 2018. As an aside GE did say they were happy with their progress in creating value and also that DMD could be absolutely huge by the end of 2018. I would like to hope so but the latter comment at least should be taken with a pinch of salt until data is in. However, I would have thought it a most unwise statement to make in the absence of confidence in trials progress?'
14/12/2017
22:24
stephen2010: ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
09/11/2017
12:12
football: The only problem with a "Great RNS" you get the feeling as soon as the share price goes up they will be another RNS stating share options or free shares to the board again dilating the stock.
24/10/2017
19:51
luminoso: I am not too worried about the Nasdaq losing its love for SUMM in the short term. The perception is that there will be no earth shattering news for some time now, so they are selling off. This can change in a flash with unexpected news as we have seen several times in past year. Apologies if I seem complacent but see nothing to be unduly worried about. Share price is not always a reliable indicator of a company's health, but is a good indicator of the mental health of traders.
21/9/2017
15:02
football: Got another holding RNS today, they seem to be like buses none for ages then to come along at once https://uk.advfn.com/stock-market/london/summit-corp-SUMM/share-news/Summit-Therapeutics-plc-Summit-Therapeutics-Plc/75699207
08/9/2017
16:19
hugus maximus: I know many of us are very optimistic about the value of Summits DMD work but find it difficult to quantify quite what the market cap might one day be. So an interesting post about Sarpeta (see below) that is very encouraging when you refer it's detail to the outlook for Summit. It explains how they are now advancing on further Exon skipping work that may help a further 8% of boys (in addition to their current 13% ... making a maximum of 21% of the DMD population that Sarepta could potentially help ... as opposed to Summit's potential 100%) Then whilst comparing the above, there seems to be much speculation about Sarepta's potential for acquisition: "As time passes and risk is reduced, the price tag for potential acquirers continues to move upward ... I'd say any deal at this point would conservatively start a share price of no less than $80," (EDIT - THAT WOULD MEAN THE SARPETA DMD WORK THEN PRESENTS A COMPANY MARKET CAP OF APPROX $4.5 billion) "... with such a price target still achievable simply by continuing to execute on the commercial side while progressing the DMD pipeline through the clinic. Recent price targets set by Oppenheimer ($76), Credit Suisse ($81), Nomura ($84) and Needham ($75) suggest I'm not too far off." Clearly this writer is a fan of Sarepta, but still an interesting measure of potential for work in the DMD field. I know Glyn acknowledged, whilst chatting at the last AGM, Summit will also be very ripe for the pickings if DMD P2 results start to show something positive. The article in full here: https://seekingalpha.com/article/4105275-sarepta-therapeutics-golodirsen-data-gamechanger?auth_param=14hlvi:1cr5eml:98faaebac416af4bfb766fc48a2ef783&dr=1#alt2
15/3/2017
11:02
football: Rns Summit Therapeutics plc Summit Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference Oxford, UK, 15 March 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the Oppenheimer 27(th) Annual Healthcare Conference, 22 March 2017 at 2:10pm EDT in New York City. A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation http://uk.advfn.com/stock-market/london/summit-corp-SUMM/share-news/Summit-Therapeutics-plc-Summit-Therapeutics-To-Pre/74098359
14/2/2017
17:05
hugus maximus: I am no accountant but would expect a more modest $500 million per year C Diff market (that figure clearly dependent on whatever the drug's market price is) ... my stab at expectations over the next few months for C Diff:- As a consequence of a 3rd party major Pharma involvement with C Diff, might Summit realistically be looking for a downpayment of say $75 - 100 million and up to a 30% royalty? Therefore the initial C Diff drug effect on share price stabilising at around £3 ... until further income is eventually generated by sales which would then enhance the share price greatly? (The above having no bearing whatsoever on DMD share price enhancement which is obviously the big prize)
10/1/2017
23:47
hugus maximus: IMO Sarpeta share interest is a consequence of them finally rolling out eteplirsen after a slow start and the announcement to that effect (a couple of days ago) brings their FDA promise toward some sort of actual fruition. Hence Sarepta's slow drop in share price in the months after the FDA approval date, was due to expectations not being met quickly enough (both in demand and supply). There were many reports of difficulties until this weeks announcement that things had turned around. I wonder if their pipe line Exon 51 is too much a part of the distant future to produce todays share price effect ... although will perhaps have endorsed their position slightly? Maybe Summit are riding on Sarepta's coat tails and the market has turned from hot to cold to warm again about wariness of DMD market in general? Let's hope that the improved eteplirsen pipeline holds for a while, allowing Summit to come in with some serious guns blazing and their shares being bought on their own terms. IMO If Summit can prove with their empirical full comprehensive clinical testing that Ezutromid stands up to the plate (as opposed to the more subjective eteplisen research work which still casts elements of doubt), the DMD market will finally and categorically be banging at their door. EDIT - unless I've missed something majorly significant announced at the San Fran Health Conference which made Summit's shares move up independently last night?
Summit Corp share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180121 20:42:55